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Despite striking results, clinical outcome with immune checkpoint inhibitors remains too often 
uncertain. This joint-project aims at generating dense longitudinal data in lung cancer patients 
undergoing anti-PD1 or anti-PDL1 therapy, alone or in combination with other anticancer 
agents.  Mathematical modelling with mechanistic learning algorithms will be used next to 
decipher the mechanisms underlying response or resistance to immunotherapy. Ultimately, 
this project should help to better understand the mechanisms underlying resistance to 






The era of precision medicine mostly relies on identifying biomarkers likely to help oncologists 
forecasting clinical outcome.  Immune checkpoint inhibitors are game-changing drugs in 
oncology, as some cancers with once dismal prognosis show now survival rates that count in 
years. Non-small cell lung cancer is typically a disease which clinical outcome has been 
dramatically improved over a short period of time with first targeted therapies and then the 
successive approvals of anti-PD1 and anti-PDL1 biologics (1). However, after the initial frenzy 
ignited by promising phase-3 trials with nivolumab, pembrolizumab or more recently 
atezolizumab, alone or in combination with standard chemotherapy, many questions remain 
unsolved. In particular, the lack of robust and fully validated biomarkers for predicting 
response to immune checkpoint inhibitors (ICIs) remains a major issue. PDL1 expression, 
tumor mutational burden, initial tumor size, history of steroids or antibiotics use, MSI status, 
gut microbiota characteristics have all been pointed independently as possible factors 
impacting on response or survival in patients treated next with ICIs (2-4). However, many 
uncertainties remain, essentially because of possible confounding factors, and the lack of 
global understanding of the utterly complex interplay between drugs, immune system, tumor 
cells, tumor micro-environment, plus all physio-pathological parameters and patients 
characteristics likely to interfere with harnessing tumor  immunity (5). Consequently, in many 
respect treating patients with immunotherapy looks like a big lottery - the winning tickets (i.e., 
response or remission with no or little immune-related toxicities) being apparently distributed 
randomly among patients (6). In this context, association between clinical investigators, 
biologists, mathematicians and industrials is crucial to accurately exploit big clinical and 
biomarkers data and stratify patients prior to therapeutic decision. The PIONeeR project is  
built upon a large biomarkers program and a randomized, umbrella clinical trial aiming at 
understanding, predicting and overcoming resistance to PD1 and PDL1 immune checkpoint 
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inhibitors. The study (NCT03493581)  first investigates a wide panel of putative tissue and 
liquid biomarkers aiming at deciphering the immune contexture in 450 advanced lung cancer 
patients treated with either nivolumab, pembrolizumab or atezolizumab alone or in 
combination with chemotherapy. Tested biomarkers include advanced 
immunohistochemistry coupled to digital pathology analyses such as CD8+/PDL1+ co-
localization (Immunoscore®) or complex immune cell populations localization and 
quantification including Myeloid Derived Suppressor Cells, blood immune-monitoring 
including rare cell subsets,  genomics and transcriptomics, gut microbiota exploration, , study 
of vascular factors, pharmacokinetics and PK/PD modelling. Both progressors and responding 
patients are closely monitored so as to better uncover unbiased predictive biomarkers. 
Patients with progressive disease before 24 weeks of treatment will be next further 
randomized in a second clinical step testing at least 3 combinatorial regimens of targeted 
therapies with anti-PDL1 durvalumab with full longitudinal monitoring as well.   The primary 
objective is to highlight immune algorithms predicting anti-PD1/L1 primary and adaptive 
resistance to stratify patients prior to ICI treatment. Importantly, all the collected data will be 
used next as part of the QUANTIC add-on project, which is an original collaboration between 
French National Institute for Research on Computer Science and Applied Mathematics (best 
known as INRIA) and the PIONeeR consortium.  The primary objective of QUANTIC is to 
develop and validate a mechanistic, dynamic model of response and resistance to immune-
checkpoint inhibition leveraging the unique, large scale, multi-modal and longitudinal data 
collected during the PIONeeR clinical study. Indeed, artificial intelligence techniques are 
required to analyze the ”big data” generated by PIONeeR (e.g., immunomonitoring alone will 
result in hundreds of quantitative variables per time point, per patient) plus additional  APHM 
routine patients (i.e.,  521 NSCLC patients that have received anti-PD1/PDL1 treatment over 
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the last 5 years). On the other hand, mechanistic modelling consists in designing 
physiologically-based mathematical constructs for the systemic kinetics of the disease and its 
response to ICIs. Such models have superior value to artificial intelligence algorithms because 
they are interpretable. This allows them to account for the biological meaning of part of the 
data (e.g. quantification of immune players) and to test biological hypotheses, which improves 
our mechanistic understanding of the processes at play. However, the fact that not all the data 
have a biological meaning, combined to the large number of variables in some data modalities 
(e.g., genomics or immune-monitoring), as well as the requirement for nonlinear covariate 
models are all rationales to keep parts of the modelling biologically agnostic, i.e. relying on 
machine learning alone. As stated above, the major clinical challenge with immunotherapy 
today is the wide inter-individual heterogeneity in response to ICIs. To address this issue and 
quantify this variability, mixed-effects statistical learning will be used for the first time. All 
patients’ data will be pooled together for the learning process, which strengthens estimation 
of the mechanistic parameters. Machine learning for inclusion of baseline covariates will 
further yield new algorithms able to predict the response/relapse patterns, including possible 
pseudo- or hyper- progression. Finally, model parameters and longitudinal analysis will be 
used to predict overall survival. This unique and entire multi-modal framework for mechanistic 
description and prediction of longitudinal kinetics of hundreds of coupled biomarkers will go 
much beyond the current state-of-the art in clinical quantitative modeling since most of the 
current studies model only the sum of longest diameters from RECIST target lesions as 
readouts.  
Overall, the PIONeeR and QUANTIC projects highlight how state-of-the art computational 
oncology, biomarker-based investigations and clinical trials should join their forces for 
deciphering the complex mechanisms explaining the variability in clinical outcomes with 
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immunotherapy (7).  As such, it should bring substantial progress for in depth understanding 
of resistance to ICIs in advanced lung cancer patients.  The final mathematical models will be 
used in the future as a new powerful tool for decision-making, i.e. by clustering patients prior 
to start the immunotherapy through a unique combination of somatic and germinal traits. In 
addition, depending on the actionable items that will have emerged from the project (e.g., 
drug exposure parameters calling for adaptive dosing strategies), patients once doomed to 
progress upon immunotherapy will benefit from customized treatment so as to increase their 
odds of success.   
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Cancer (grant #19CM148-00).  
 
References 
1. Ackermann CJ, Reck M, Paz-Ares L, Barlesi F, Califano R. First-line immune checkpoint 
blockade for advanced non-small-cell lung cancer: Travelling at the speed of light. Lung 
Cancer  134, 245-253 (2019). 
2. Hofman P, Heeke S, Alix-Panabières C, Pantel K. Liquid biopsy in the era of immuno-




3. Willis C, Fiander M, Tran D, Korytowsky B, Thomas JM, Calderon F et al. Tumor 
mutational burden in lung cancer: a systematic literature review. Oncotarget 10, 6604-
6622 (2019). 
4. Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H et al. Negative 
association of antibiotics on clinical activity of immune checkpoint inhibitors in 
patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 29, 1437-
1444 (2018). 
5. Remon J, Vilariño N, Reguart N. Immune checkpoint inhibitors in non-small cell lung 
cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. 
Cancer Treat Rev 64, 21-29 (2018).  
6. Ciccolini J, Barbolosi D, André N, Benzekry S, Barlesi F. Combinatorial immunotherapy 
strategies: most gods throw dice, but fate plays chess. Ann Oncol 30, 1690-1691 (2019). 
7. Barbolosi D, Ciccolini J, Lacarelle B, Barlési F, André N. Computational oncology--
mathematical modelling of drug regimens for precision medicine. Nat Rev Clin Oncol 
13, 242-54 (2016). 
 
